Please Wait.....
Report
Global Pancreatic Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2023-01-01 I 700 Pages I Data Bridge Market Research
The global pancreatic cancer diagnostics market is projected to register a substantial CAGR of 7.5% from 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030.
Market Segmentation:
Global Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type(Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application(Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland and the Rest of Europe, China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan and the Rest of Asia-Pacific, South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel and the Rest of Middle East and Africa, Brazil, Argentina, and the Rest of South America) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of global pancreatic cancer diagnostics market are:
- Rise in prevalence and incidence of pancreatic cancer
- Increase in awareness about the pancreatic cancer diagnostics
Market Players:
Some of the major players operating in the global pancreatic cancer diagnostics market are:
- Canon Medical Systems ANZ Pty Limited.
- Koninklijke Philips N.V.
- Siemens Healthcare Private Limited
- Grail
- Myriad Genetics, Inc.
- BD
- Boditech Med Inc.
- Abbott
- FUJIFILM Holdings America Corporation
- Agilent Technologies, Inc.
- Thermo Fisher Scientific
- QIAGEN
- MP BIOMEDICALS
- Laboratory Corporation of America Holdings
- CTK Biotech, Inc.
- AccuBioTech Co., Ltd.
- DiaSource
- Setia Scientific Solution
- Creative Biolabs
- Meridian Life Science, Inc.
- Lee Biosolutions, Inc
TABLE OF CONTENTS
1 INTRODUCTION 92
1.1 OBJECTIVES OF THE STUDY 92
1.2 MARKET DEFINITION 92
1.3 OVERVIEW OF THE GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET 92
1.4 CURRENCY AND PRICING 95
1.5 LIMITATIONS 95
1.6 MARKETS COVERED 95
2 MARKET SEGMENTATION 99
2.1 MARKETS COVERED 99
2.2 GEOGRAPHICAL SCOPE 100
2.3 YEARS CONSIDERED FOR THE STUDY 101
2.4 DBMR TRIPOD DATA VALIDATION MODEL 102
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 105
2.6 MULTIVARIATE MODELLING 106
2.7 MARKET END USER COVERAGE GRID 107
2.8 PRODUCT LIFELINE CURVE 108
2.9 DBMR MARKET POSITION GRID 109
2.10 VENDOR SHARE ANALYSIS 110
2.11 SECONDARY SOURCES 111
2.12 ASSUMPTIONS 111
3 EXECUTIVE SUMMARY 112
4 PREMIUM INSIGHTS 115
4.1 PESTEL ANALYSIS 118
4.2 PORTER'S FIVE FORCES MODEL 119
5 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS 120
6 EPIDEMIOLOGY 122
7 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS 123
8 MARKET OVERVIEW 126
8.1 DRIVERS 128
8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER 128
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS 128
8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 129
8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER 129
8.2 RESTRAINTS 130
8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS 130
8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER 130
8.3 OPPORTUNITIES 131
8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER 131
8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 132
8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS 132
8.4 CHALLENGES 133
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 133
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 133
9 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE 134
9.1 OVERVIEW 135
9.2 IMAGING TEST 138
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 139
9.2.2 MAGNETIC RESONANCE IMAGING (MRI) 139
9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY 139
9.2.2.2 MR ANGIOGRAPHY (MRA) 140
9.2.3 ULTRASOUND 140
9.2.3.1 ABDOMINAL ULTRASOUND 140
9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS) 140
9.2.4 CHOLANGIOPANCREATOGRAPHY 140
9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) 141
9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) 141
9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC) 141
9.2.5 POSITRON EMISSION TOMOHRAPHY (PET) 141
9.2.6 OTHERS 141
9.3 BIOPSY 142
9.3.1 CT-GUIDED NEEDLE BIOPSY 143
9.3.2 FINE NEEDLE ASPIRATION (FNA) 143
9.3.3 CORE NEEDLE BIOPSY 143
9.3.4 OTHERS 143
9.4 BLOOD TEST 143
9.4.1 LIVER FUNCTION TEST 144
9.4.2 TUMOR MARKER 144
9.4.2.1 CA 19-9 BIOMARKER TEST 145
9.4.2.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST 145
9.4.2.3 CA 50 MARKER TEST 145
9.4.2.4 OTHERS 145
9.4.3 OTHERS 145
9.5 GENOMIC TEST 146
9.6 OTHERS 147
10 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 148
10.1 OVERVIEW 149
10.2 STAGE IV 152
10.3 STAGE III 152
10.4 STAGE II 153
10.4.1 STAGE IIA 154
10.4.2 STAGE IIB 154
10.5 STAGE I 154
10.5.1 STAGE IA 155
10.5.2 STAGE IB 155
10.6 STAGE 0 156
11 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 157
11.1 OVERVIEW 158
11.2 EXOCRINE TUMORS 161
11.2.1 INSTRUMENT-BASED PRODUCTS 162
11.2.2 PLATFORM-BASED PRODUCTS 162
11.2.3 KITS AND REAGENTS 162
11.2.4 OTHER CONSUMABLES 162
11.3 NEUROENDOCRINE TUMORS 162
11.3.1 INSTRUMENT-BASED PRODUCTS 163
11.3.2 PLATFORM-BASED PRODUCTS 163
11.3.3 KITS AND REAGENTS 164
11.3.4 OTHER CONSUMABLES 164
12 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT 165
12.1 OVERVIEW 166
12.2 INSTRUMENT-BASED PRODUCTS 169
12.2.1 IMAGING 170
12.2.2 BIOPSY 170
12.3 PLATFORM-BASED PRODUCTS 170
12.3.1 NEXT-GENERATION SEQUENCING 171
12.3.2 MICROARRAYS 171
12.3.3 PCR 171
12.3.4 OTHERS 172
12.4 KITS AND REAGENTS 172
12.4.1 CA19-9 PANCREATIC CANCER TEST KITS 173
12.4.1.1 ELISA TEST KITS 173
12.4.1.2 CASETTE TEST KITS 173
12.4.1.3 OTHERS 173
12.4.2 CEA PANCREATIC CANCER TEST KITS 174
12.4.2.1 ELISA TEST KITS 174
12.4.2.2 CASETTE TEST KITS 174
12.4.2.3 OTHERS 174
12.5 OTHER CONSUMABLES 174
13 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 176
13.1 OVERVIEW 177
13.2 FLUORESCENT IN SITU HYBRIDIZATION 180
13.3 NEXT GENERATION SEQUENCING 181
13.4 FLUORIMMUNOASSAY 182
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 183
13.6 IMMUNOHISTOCHEMICAL 184
13.7 OTHERS 185
14 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 186
14.1 OVERVIEW 187
14.2 SCREENING 190
14.2.1 INSTRUMENT-BASED PRODUCTS 191
14.2.2 PLATFORM-BASED PRODUCTS 191
14.2.3 KITS AND REAGENTS 191
14.2.4 OTHER CONSUMABLES 191
14.3 DIAGNOSTIC AND PREDICTIVE 191
14.3.1 INSTRUMENT-BASED PRODUCTS 192
14.3.2 PLATFORM-BASED PRODUCTS 192
14.3.3 KITS AND REAGENTS 192
14.3.4 OTHER CONSUMABLES 192
14.4 PROGNOSTIC 193
14.4.1 INSTRUMENT-BASED PRODUCTS 194
14.4.2 PLATFORM-BASED PRODUCTS 194
14.4.3 KITS AND REAGENTS 194
14.4.4 OTHER CONSUMABLES 194
14.5 RESEARCH 194
14.5.1 INSTRUMENT-BASED PRODUCTS 195
14.5.2 PLATFORM-BASED PRODUCTS 195
14.5.3 KITS AND REAGENTS 195
14.5.4 OTHER CONSUMABLES 195
15 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 196
15.1 OVERVIEW 197
15.2 HOSPITALS 200
15.3 DIAGNOSTIC CENTERS 200
15.4 CANCER RESEARCH CENTERS 201
15.5 ACADEMIC INSTITUTES 202
15.6 AMBULATORY SURGICAL CENTERS 203
15.7 OTHERS 204
16 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 205
16.1 OVERVIEW 206
16.2 DIRECT TENDER 209
16.3 RETAIL SALES 210
16.4 OTHERS 211
17 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 212
17.1 OVERVIEW 213
17.2 NORTH AMERICA 219
17.2.1 U.S. 233
17.2.2 CANADA 242
17.2.3 MEXICO 251
17.3 EUROPE 260
17.3.1 GERMANY 275
17.3.2 FRANCE 284
17.3.3 UNITED KINGDOM 293
17.3.4 ITALY 302
17.3.5 SPAIN 311
17.3.6 RUSSIA 320
17.3.7 NETHERLANDS 329
17.3.8 POLAND 338
17.3.9 SWITZERLAND 347
17.3.10 BELGIUM 356
17.3.11 SWEDEN 365
17.3.12 NORWAY 374
17.3.13 DENMARK 383
17.3.14 FINLAND 392
17.3.15 TURKEY 401
17.3.16 REST OF EUROPE 410
17.4 ASIA-PACIFIC 411
17.4.1 CHINA 424
17.4.2 JAPAN 432
17.4.3 INDIA 440
17.4.4 SOUTH KOREA 448
17.4.5 AUSTRALIA 456
17.4.6 TAIWAN 464
17.4.7 NEW ZEALAND 472
17.4.8 INDONESIA 480
17.4.9 THAILAND 488
17.4.10 PHILIPPINES 496
17.4.11 MALAYSIA 504
17.4.12 VIETNAM 512
17.4.13 SINGAPORE 520
17.4.14 REST OF ASIA-PACIFIC 528
17.5 SOUTH AMERICA 529
17.5.1 BRAZIL 542
17.5.2 ARGENTINA 550
17.5.3 REST OF SOUTH AMERICA 558
17.6 MIDDLE EAST AND AFRICA 559
17.6.1 SOUTH AFRICA 574
17.6.2 SAUDI ARABIA 583
17.6.3 BAHRAIN 592
17.6.4 UAE 601
17.6.5 EGYPT 610
17.6.6 ISRAEL 619
17.6.7 KUWAIT 628
17.6.8 OMAN 637
17.6.9 QATAR 646
17.6.10 REST OF MIDDLE EAST AND AFRICA 655
18 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 656
18.1 COMPANY SHARE ANALYSIS: GLOBAL 656
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 657
18.3 COMPANY SHARE ANALYSIS: EUROPE 658
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 659
19 SWOT ANALYSIS 660
20 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET 661
20.1 CANON MEDICAL SYSTEMS CORPORATION 661
20.1.1 COMPANY SNAPSHOT 661
20.1.2 REVENUE ANALYSIS 661
20.1.3 COMPANY SHARE ANALYSIS 662
20.1.4 PRODUCT PORTFOLIO 662
20.1.5 RECENT DEVELOPMENT 662
20.2 KONINKLIJKE PHILIPS N.V. 663
20.2.1 COMPANY SNAPSHOT 663
20.2.2 REVENUE ANALYSIS 663
20.2.3 COMPANY SHARE ANALYSIS 664
20.2.4 PRODUCT PORTFOLIO 664
20.2.5 RECENT DEVELOPMENTS 664
20.3 SIEMENS HEALTHCARE GMBH 666
20.3.1 COMPANY SNAPSHOT 666
20.3.2 REVENUE ANALYSIS 666
20.3.3 COMPANY SHARE ANALYSIS 667
20.3.4 PRODUCT PORTFOLIO 667
20.3.5 RECENT DEVELOPMENT 668
20.4 GRAIL 669
20.4.1 COMPANY PROFILE 669
20.4.2 COMPANY SHARE ANALYSIS 669
20.4.3 PRODUCT PORTFOLIO 670
20.4.4 RECENT DEVELOPMENT 670
20.5 MYRIAD GENETICS, INC. 671
20.5.1 COMPANY SNAPSHOT 671
20.5.2 REVENUE ANALYSIS 671
20.5.3 COMPANY SHARE ANALYSIS 672
20.5.4 PRODUCT PORTFOLIO 672
20.5.5 RECENT DEVELOPMENT 672
20.6 BD 673
20.6.1 COMPANY SNAPSHOT 673
20.6.2 REVENUE ANALYSIS 673
20.6.3 PRODUCT PORTFOLIO 674
20.6.4 RECENT DEVELOPMENT 674
20.7 BODITECH MED INC. 675
20.7.1 COMPANY PROFILE 675
20.7.2 PRODUCT PORTFOLIO 675
20.7.3 RECENT DEVELOPMENT 675
20.8 ABBOTT (2022) 676
20.8.1 COMPANY SNAPSHOT 676
20.8.2 REVENUE ANALYSIS 676
20.8.3 PRODUCT PORTFOLIO 677
20.8.4 RECENT DEVELOPMENT 677
20.9 FUJIFILM HOLDINGS AMERICA CORPORATION 678
20.9.1 COMPANY SNAPSHOT 678
20.9.2 REVENUE ANALYSIS 678
20.9.3 PRODUCT PORTFOLIO 679
20.9.4 RECENT DEVELOPMENT 679
20.10 ACCUBIOTECH CO., LTD. 680
20.10.1 COMPANY PROFILE 680
20.10.2 PRODUCT PORTFOLIO 680
20.10.3 RECENT DEVELOPMENTS 680
20.11 AGILENT TECHNOLOGIES, INC. 681
20.11.1 COMPANY PROFILE 681
20.11.2 REVENUE ANALYSIS 681
20.11.3 PRODUCT PORTFOLIO 682
20.11.4 RECENT DEVELOPMENT 682
20.12 CREATIVE BIOLABS. 683
20.12.1 COMPANY PROFILE 683
20.12.2 PRODUCT PORTFOLIO 683
20.12.3 RECENT DEVELOPMENT 683
20.13 CTK BIOTECH, INC. 684
20.13.1 COMPANY PROFILE 684
20.13.2 PRODUCT PORTFOLIO 684
20.13.3 RECENT DEVELOPMENT 684
20.14 DIASOURCE 685
20.14.1 COMPANY SNAPSHOT 685
20.14.2 PRODUCT PORTFOLIO 685
20.14.3 RECENT DEVELOPMENT 685
20.15 LABORATORY CORPORATION OF AMERICA HOLDINGS 686
20.15.1 COMPANY SNAPSHOT 686
20.15.2 REVENUE ANALYSIS 686
20.15.3 PRODUCT PORTFOLIO 687
20.15.4 RECENT DEVELOPMENTS 687
20.16 LEE BIOSCIENCE 688
20.16.1 COMPANY SNAPSHOT 688
20.16.2 PRODUCT PORTFOLIO 688
20.16.3 RECENT DEVELOPMENT 688
20.17 MERIDIAN BIOSCIENCE INC. 689
20.17.1 COMPANY PROFILE 689
20.17.2 PRODUCT PORTFOLIO 689
20.17.3 RECENT DEVELOPMENT 689
20.18 MP BIOMEDICALS. 690
20.18.1 COMPANY PROFILE 690
20.18.2 PRODUCT PORTFOLIO 690
20.18.3 RECENT DEVELOPMENTS 690
20.19 QIAGEN 691
20.19.1 COMPANY SNAPSHOT 691
20.19.2 REVENUE ANALYSIS 691
20.19.3 PRODUCT PORTFOLIO 692
20.19.4 RECENT DEVELOPMENT 692
20.20 SETIA SCIENTIFIC SOLUTION 693
20.20.1 COMPANY PROFILE 693
20.20.2 PRODUCT PORTFOLIO 693
20.20.3 RECENT DEVELOPMENTS 693
20.21 THERMO FISHER SCIENTIFIC INC. 694
20.21.1 COMPANY SNAPSHOT 694
20.21.2 REVENUE ANALYSIS 694
20.21.3 PRODUCT PORTFOLIO 695
20.21.4 RECENT DEVELOPMENT 695
21 QUESTIONNAIRE 696
22 RELATED REPORTS 700
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security